Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER
Brief Summary: A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer.


Options:
A: Arm Label: avelumab; Type: EXPERIMENTAL; Interventions: Biological: avelumab | Arm Label: avelumab plus pegylated liposomal doxorubicin (PLD); Type: EXPERIMENTAL; Interventions: Biological: avelumab, Drug: PLD | Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD | Intervention Type: BIOLOGICAL; Name: avelumab; Assigned to Arm(s): avelumab, avelumab plus pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): PLD, avelumab plus pegylated liposomal doxorubicin (PLD)
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C
D: Arm Label: Arm I (adjuvant chemotherapy suboptimally debulked); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Arm Label: Arm II (neoadjuvant chemotherapy); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Procedure: Computed Tomography, Drug: Paclitaxel, Procedure: Therapeutic Conventional Surgery | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy) | Intervention Type: PROCEDURE; Name: Therapeutic Conventional Surgery; Assigned to Arm(s): Arm I (adjuvant chemotherapy suboptimally debulked), Arm II (neoadjuvant chemotherapy)

Answer: A